Mirum Pharmaceuticals receives Health Canada authorization for Livmarli tablet

Mirum Pharmaceuticals (MIRM) announced that Health Canada has authorized the tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille syndrome. Livmarli had previously been authorized in Canada as an oral solution for patients aged 12 months or older. The new tablet formulation offers an additional dosing option for patients weighing 22 kg or more who can swallow tablets. “LIVMARLI’s tablet formulation provides an important new option for patients with ALGS,” said Jamie Twiselton, general manager, Mirum Pharmaceuticals Canada. “With a liquid formulation for younger patients and a convenient one tablet per dose option available for older patients, LIVMARLI now provides greater dosing flexibility, supporting continuity of care as patients with ALGS age.”